LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Akciju saraksts・Pulmatrix Inc

Pulmatrix Inc

Slēgts

2.4 2.56

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.3

Max

2.4699999999999998

Galvenie mērījumi
By Trading Economics
Ienākumi	672K -877K
EPS	-0.24
Peļņas marža	-60,266.667
Darbinieki	2
EBITDA	671K -877K

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-8.9M 9M
Iepriekšējā atvēršanas cena	-0.16
Iepriekšējā slēgšanas cena	2.4

Pulmatrix Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. febr. 16:32 UTC

Peļņas

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

2026. g. 13. febr. 21:57 UTC

Peļņas

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

2026. g. 13. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 13. febr. 21:20 UTC

Peļņas

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

2026. g. 13. febr. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

2026. g. 13. febr. 20:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 13. febr. 20:45 UTC

Tirgus saruna

Dollar Pares Down Early Losses -- Market Talk

2026. g. 13. febr. 20:39 UTC

Tirgus saruna

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

2026. g. 13. febr. 20:28 UTC

Tirgus saruna

Oil Settles Week Lower -- Market Talk

2026. g. 13. febr. 19:51 UTC

Peļņas

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026. g. 13. febr. 19:32 UTC

Tirgus saruna

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026. g. 13. febr. 19:32 UTC

Tirgus saruna

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026. g. 13. febr. 19:29 UTC

Peļņas

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

2026. g. 13. febr. 18:18 UTC

Iegādes, apvienošanās, pārņemšana

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

2026. g. 13. febr. 17:52 UTC

Peļņas

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

2026. g. 13. febr. 17:16 UTC

Peļņas

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026. g. 13. febr. 17:10 UTC

Iegādes, apvienošanās, pārņemšana

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

2026. g. 13. febr. 16:59 UTC

Peļņas

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

2026. g. 13. febr. 16:39 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

2026. g. 13. febr. 16:11 UTC

Peļņas

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

2026. g. 13. febr. 16:07 UTC

Tirgus saruna

Hungarian Forint Could Rise Further -- Market Talk

2026. g. 13. febr. 15:54 UTC

Peļņas

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

2026. g. 13. febr. 15:26 UTC

Tirgus saruna

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

2026. g. 13. febr. 15:01 UTC

Peļņas

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

2026. g. 13. febr. 15:00 UTC

Peļņas

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

2026. g. 13. febr. 14:50 UTC

Tirgus saruna

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

2026. g. 13. febr. 14:44 UTC

Peļņas

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

2026. g. 13. febr. 14:22 UTC

Tirgus saruna

Peļņas

Global Energy Roundup: Market Talk

2026. g. 13. febr. 14:21 UTC

Tirgus saruna

Peļņas

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

2026. g. 13. febr. 14:13 UTC

Tirgus saruna

U.S. Natural Gas Futures Move Lower -- Market Talk

Salīdzinājums

Cenas izmaiņa

Pulmatrix Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pulmatrix Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.